Effects of SGLT2 inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice - Tahara, A; Kurosaki, E; Yokono, M (Eur J Pharmacol, 2013)
et al.